These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11262217)

  • 61. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis.
    Bergmann JS; Woods GL
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):621-6. PubMed ID: 9712275
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
    Yee DP; Menzies D; Brassard P
    Int J Tuberc Lung Dis; 2012 May; 16(5):604-9. PubMed ID: 22409887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
    Paramasivan CN; Sulochana S; Kubendiran G; Venkatesan P; Mitchison DA
    Antimicrob Agents Chemother; 2005 Feb; 49(2):627-31. PubMed ID: 15673743
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1610-6. PubMed ID: 8807049
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model.
    Sarkar S; Sarkar D
    J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
    Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
    BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
    Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems.
    Tortoli E; Mattei R; Savarino A; Bartolini L; Beer J
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):83-6. PubMed ID: 11035238
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of antituberculous drugs, isoniazid, pyrazinamide and rifampicin, on chemiluminescence of the human polymorphonuclear leukocytes.
    Demkow U; Małkowska-Zwierz W; Rogala E; Skopińska-Rózewska E; Lewandowski Z
    Folia Biol (Praha); 1995; 41(5):257-62. PubMed ID: 8714775
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
    Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
    J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
    Smith PJ; van Dyk J; Fredericks A
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
    Herbert D; Paramasivan CN; Venkatesan P; Kubendiran G; Prabhakar R; Mitchison DA
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2296-9. PubMed ID: 8891133
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs.
    Tomioka H; Sato K; Shimizu T; Sano C
    J Infect; 2002 Apr; 44(3):160-5. PubMed ID: 12099742
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
    Gumbo T
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1484-91. PubMed ID: 20086150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.